10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

SFRS2 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP2800a

Product Information

Application	WB, IHC-P, E
Primary Accession	Q01130
Other Accession	Q6PDU1, Q06A98, Q62093, P30352, Q3MHR5
Reactivity	Human
Predicted	Mouse, Rat, Pig, Chicken, Bovine, Canine
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB17329
Calculated MW	25476
Antigen Region	9-39

Additional Information

Gene ID	6427
Other Names	Serine/arginine-rich splicing factor 2, Protein PR264, Splicing component, 35 kDa, Splicing factor SC35, SC-35, Splicing factor, arginine/serine-rich 2, SRSF2, SFRS2
Target/Specificity	This SFRS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 9-39 amino acids from the N-terminal region of human SFRS2.
Dilution	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	SFRS2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	SRSF2
Synonyms	SFRS2

Function	Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment.
Cellular Location	Nucleus. Nucleus, nucleoplasm. Nucleus speckle. Note=Phosphorylation by SRPK2 provokes its redistribution from the nuclear speckle to nucleoplasm


Background

SFRS2 is necessary for the splicing of pre-mRNA. The protein is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. And it interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. It binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3' and can bind to beta-globin mRNA and commit it to the splicing pathway.


References

Merdzhanova,G., Cell Death Differ. 15 (12), 1815-1823 (2008) Solis,A.S., J. Biol. Chem. 283 (35), 23619-23626 (2008) Donev,R., Mol. Psychiatry 12 (7), 681-690 (2007) Sureau,A., Proc. Natl. Acad. Sci. U.S.A. 89 (24), 11683-11687 (1992)

Images



All lanes: Anti-SFRS2 Antibody (N-term) at 1:1000 dilution Lane 1: HepG2 whole cell lysate Lane 2: 293 whole cell lysate Lane 3: HL-60 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 30 KDa Blocking/Dilution buffer: 5% NFDM/TBST.



Formalin-fixed and paraffin-embedded human lung carcinoma tissue reacted with SFRS2 antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.